Section of Immunology and Infection, Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK,
BioDrugs. 2013 Dec;27(6):559-63. doi: 10.1007/s40259-013-0047-0.
It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of interleukin (IL)-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were, for the most part, disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review summarises the current evidence, demonstrating the effectiveness or otherwise of the targeting of IL-5 in patients with asthma.
人们认识到气道炎症是哮喘发病机制的关键。生物制药方法已经确定了新的治疗方法，这些方法针对的是驱动哮喘肺部炎症反应的关键细胞和介质。这种方法导致了针对白细胞介素 (IL)-4、IL-5 和 IL-13 抑制的生物制剂的开发。然而，这些生物制剂在哮喘患者中的早期临床试验在很大程度上令人失望，尽管它们在哮喘动物模型中非常有效。越来越明显的是，基于抗细胞因子的治疗在考虑哮喘表型的精心挑选的患者人群中更有可能产生显著的临床效果。鉴别性生物标志物和基因分析的发展可能有助于识别此类哮喘患者。这篇综述总结了目前的证据，证明了针对哮喘患者的 IL-5 靶向治疗的有效性或无效性。
